薬物-標的のレジデンスタイムの理解と創薬への影響

Liuら（Wed,）はこの問題を研究した。

www.synapsesocial.com/papers/6973106cc8125b09b0d20292 — DOI: https://doi.org/10.1080/17460441.2026.2619070

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Understanding the Differences of Danusertib’s Residence Time in Aurora Kinases A/B: Dissociation Paths and Key Residues Identified using Conventional and Enhanced Molecular Dynamics Simulations· 2024 · 2 citations
2. Long-Residence Time Peptide Antagonist for the Vasopressin V₂ Receptor to Treat Autosomal Dominant Polycystic Kidney Disease· 2024 · 4 citations
3. Phase II and phase III failures: 2013–2015· 2016 · 606 citations
4. Evaluation of Enzyme Inhibitors in Drug Discovery· 2013 · 668 citations
5. Estimation of Drug-Target Residence Time by Targeted Molecular Dynamics Simulations· 2022 · 20 citations